Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 14, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-021-01061-x
Keywords
PARP inhibitors; Prostate cancers; Homologous recombination repair; DNA repair
Categories
Ask authors/readers for more resources
Prostate cancer remains lethal at the metastatic castration-resistant stage, and the development of PARP inhibitors offers a new therapeutic option. Despite progress, there are still issues related to PARP inhibitors that need to be addressed.
Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic alterations of DNA-damage response pathway genes are found in a substantial number of patients with advanced prostate cancers, mainly of poor prognosis. Such alterations induce a dependency for single strand break reparation through the poly(adenosine diphosphate-ribose) polymerase (PARP) system, providing the rationale to develop PARP inhibitors. In solid tumors, the first demonstration of an improvement in overall survival was provided by olaparib in patients with mCRPC harboring homologous recombination repair deficiencies. Although this represents a major milestone, a number of issues relating to PARP inhibitors remain. This timely review synthesizes and discusses the rationale and development of PARP inhibitors, biomarker-based approaches associated and the future challenges related to their prescription as well as patient pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available